ABSTRACT
Introduction
During surgical procedures, surgeons frequently face limited possibilities of therapeutic action due to the infeasibility of neoplastic tissue total resection, such as when various visceral metastases, and hepatic metastases in particular, exist 1, 2 . The major therapeutic modalitites presently used in the treatment of hepatic metastases are: surgical resection, artery ligation, embolization and chemotherapy, ablation methods (laser, radiofrequency, cryotherapy, hyperthermia, microwaves, and necrotizing and cytolytic substances) and genetic therapy 3, 4 . To this date, surgical resection, the major therapeutic modality, is the only procedure that may result in cure. Nevertheless the number of patients capable of undergoing surgery (10 -15%) is low 2 . Among palliative methods, the ablative approach is distinguished as it uses cytolytic and necrotizing substances such as alcohol or other methods, namely, cryotherapy, radiofrequency, laser and microwaves for localized lesion destruction. These methods are most frequently applied in irresectable cases 5 . It was in this setting (destruction of irresectable metastases) that our line of investigation was developed. The basic idea was to try to destroy tumoral tissue by the use of solutions or substances with cytolytic or sclerosing action. Through literature review, it was verifi ed that the injection of a solution composed of phenol, glycerin and glacial acetic acid into the prostate of dogs led to the reduction of that organ's volume, and that such reduction would be due to tissue necrosis 6 . The use of the solution was experimentally assayed in Walker's tumor hepatic metastases, leading to suggestive results of necrosis production without alterations in the clinical development of the tumor 7, 8 . In face of such characteristic diffi culties posed by hepatic metastasis therapy, new treatments must be developed with the purpose to achieve good effi cacy rates, low cost, low frequency of side effects and easy execution. Hence, experimentally investigating the possibility of using such substance (henceforth referred to as solution E) in the destruction of irresectable hepatic metastases is considered to be a worthwhile undertaking.
Methods
Thirty-two male and female guinea pigs weighing 150 to 450g were used. Prior to each experimental time, the guinea pigs were kept in fast for 8 hours with water provision ad libitum. Solution E was injected into the animals' livers and sacrifi ce occurred after 24 hours (group 1) or 4 weeks (group 2). Saline solution was injected into the animals comprising the control group and their sacrifi ce took place after 24 hours (group 3) or 4 weeks (group 4). Eight animals were used in each group, and euthanasia was performed by a lethal dose of anesthetic. The sclerosing solution was composed of phenol (0.6g), glycerin (1.2g) and glacial acetic acid (0.6g) in distilled-water solution (28.0ml), denominated solution E. Based on a pilot experiment, the use of 0.5ml of the solution was selected. The same volume of saline solution (F) was used for the control groups. A dose of nembutal, 33mg/kg of weight, was intrapleurally administered. Median laparotomy with 3 to 4cm, beginning right under the xiphoid appendix, was performed for hepatic injection. Injection was always accomplished into the upper left lobe using an insulintype syringe with a 13x4 needle. Biochemical dosing was performed after the collection of 5ml of blood by heart puncture. Blood was collected immediately prior to anesthesia and euthanasia. The methodology used was as follows: glycemia -GOP-PAP test -Automation -ABRA -100 -Reactoclinic Kit; alkaline phosphatase -(Alk. F). Spectrophotometer -Kinetic UV test -Automation -ABRA -100 -Reactoclin kit; bilirubins (Bd, Bi, Bt). MALLOY-EVELYN method -Manual -the laboratory's own kit; glutamic oxalacetic transminase (GOT) -Kinetic UV test -Automation -ABRA -100 -Reactoclìnic Kit; glutamic pyruvic transaminase (GPT) -Kinetic UV test -Automation -ABRA -100 -Kit and gamma glutamyl transferase (Gamma GT) -Kinetic UV -Automation -ABRA -100 -Reactoclinic Kit. After sacrifi ce, the animal's abdomen was opened in the median line; the liver was macroscopically examined, and slides were prepared and stained by hematoxilin for histopathological examination. Slide reading was performed without previous knowledge of the group to which they belonged.
Results

Chemical dosage
All the dosage amounts for glycemia, gamma-t, alkaline phosphatase, bilirubins, aspartate aminotranspherase and alanine aminotranspherase were within reference values, thus showing no statistically signifi cant difference in any of the dosages at the different studied moments (p>0.05). When the individual values for each animal in the experimental group were compared, it was not possible to fi nd alterations pointing to group tendency. Also, no alterations were found between the groups receiving solution E and those receiving saline solution (F).
Clinical assessment -macroscopic examination
The following phenomena were observed on the occasion of hepatic injection:
-No animals showed alterations in vital signs for and up to 5 minutes after injection of both solution E and saline solution.
-In the case of saline solution, the occurrence of a small pale area was observed around the puncture needle during injection, which was immediately followed by normalization upon completion of the procedure.
-In the case of solution E, a whitish area of approximately 1cm was formed around the infi ltration site.
Twenty-four hours later, no abnormal characteristics were observed in the animals receiving saline solution whereas those given solution E showed the presence of a white area of approximately 0.5cm in diameter with necrotic appearance which was well circumscribed and presented no laceration or bleeding. After four weeks, some animals (5) showed a small whitish mark on the site of injection of solution E. No abnormal signs were found in the others.
Histopathology
Small focal areas were found with hepatocyte basophilia on virtually all liver slides from all groups. Although less frequently, points of lymphoid infi ltrate were also observed in the portal spaces, which was not observed in the treated animals, however. Additionally, some of the animals presented variable and, in general, low-intensity levels of micro steatosis. The presence of steatosis did not vary whereas the periportal infl ammatory infi ltrate occurred only after 4 weeks, although with similar frequency in the experimental and control groups, which showed that such alteration was not related to the experiment, but probably dependent on other factors. Based on the microscopic assessment, only the animals sacrifi ced after 24 hours and which had been given hepatic infi ltration with solution E presented focal-type necrosis (Figure 1 ). After 4 weeks, only 2 animals were observed to show a fi brosis focal area corresponding to the scar seen under macroscopy. In summary, the solution produced focal liver necrosis which was repaired after 4 weeks and left minimum scars. No other histological alterations that could be attributed to the action of solution E by the sclerosing substance were found.
FIGURE1 -Histological section of a guinea pig's liver 24 hours after injection of sclerosing solution (E). Necrosis area (blue arrow). X200.HE staining 
Discussion
Guinea pigs were used as experimental animals due to the fact that such animals are very sensitive to drug effects 8 . Also, the type of anesthesia administered must be pointed out. Since venous anesthesia was not possible, and considering that ether anesthesia had led to complications as well as that the peritoneal route was not indicated due to occasional interference with the drug being tested, the use of the intrathoracic route was standardized with good results. No references to the use of such route in guinea pigs were found in the literature. A dose of 0.5ml of solution was standardized since it enabled the defi nition of an appropriate area in the liver immediately after injection. As regards body weight, the dose corresponded to 1.0 to 1.5 ml/Kg of the animal's weight. Phenol, one of the solution's components, features antiseptic (shown by Lister in the 19th century) and anesthetic action. Phenol's germicidal histotoxic action results from protein denaturation 9, 10 . According to Goodman and Gilman 10 , the solution of phenol in glycerin is less active than the aqueous solution as they report that its oral ingestion may cause mucocutaneous and gastrointestinal corrosion. In humans, phenol, at a dose of 4g, causes intoxication, and a dose of 15 to 20g may lead to death 9, 10 . Systemic toxicity 10 is shown by the transitory stimulation of the CNS, and the carcinogenic potential of phenol is disputable, according to those authors. Phenol is mainly eliminated by the kidneys, and most of it is excreted in the fi rst 24 hours 11 . Glacial acetic acid also features bactericidal action when the 5% solution in smaller concentrations is bacteriostatic 10 . In mice, the DL50 dose is 5g/Kg of weight. In humans, a lethal dose is of 15 to 30g of pure acid or 300 ml of 5% solution 10, 11 . Glycerin also has diuretic action (osmotic diuretics) and is quickly metabolized. The dose for adults is of 1 to 1.5g/Kg of weight. A daily dose must not exceed 120g 10 . In mice, its lethal dose is 31.58g/kg of weight when orally administered or 7.56g/Kg, if it is venously injected. It is known that glycerin has renal vasoconstricting action (in higher doses) and may produce renal insuffi ciency. Solution E, containing such components, was empirically used, as previously mentioned, for protatic patients in the early 21 st century in India by Roberts 6 . Since then, it has been used by other authors, but always in the prostate 6, 12 . No other similar studies to ours were found in the literature and neither were references to biochemical dosages in animals noted so as to enable comparison to our fi ndings. Alterations between the animals in the treated and control groups were not observed. The experimental groups were analyzed at 24 hours and at 4 weeks of development, since in a pilot experiment, it was observed that after 24 hours, the infi ltrated area presented rather visible necrosis, and that after 4 weeks, it would be possible to verify whether replacement by fi brous or by hepatic tissue had occurred. Our results showed that the injection of solution E into the liver did not lead to biochemical alterations related to the hepatic function. From the histopathological point of view, the injection of solution E caused a necrosis area in the infi ltrated region which was perfectly diagnosed (macro and microscopically) after 24 hours. After 4 weeks of development, necrosis was not shown, and the liver presented normal appearance during both the macroscopic and the microscopic examination; the necrosis area was replaced (only in two animals) by a small extension of minor fi brotic tissue, and normal hepatic tissue was recovered. The injection of saline solution was not followed by any anatomopathological alterations. Based on the obtained results, it is believed that the possibility of infi ltrating hepatic metastases with solution E is feasible. Through such procedure, it would be possible to destroy neoplastic cells by necrosis: the occasional destruction of hepatic tissue near the tumoral area, after a certain period of time, will probably show recovery of normal tissue with a small cicatricial area (at times).
Conclusion
In guinea pigs, the used dose (0.5ml) of the sclerosing solution (E), when infi ltrated into the liver:
1. produces necrosis.
2. necrosis is focal, limited to the infi ltrated area.
3. it is not followed by clinical alterations in the animal and does not cause mortality.
4. it is not followed by biochemical alterations related to the hepatic function.
5. recovery of hepatic tissue with mild fi brosis occurs after necrosis.
6. it is not followed by clinical alterations and no mortality takes place.
Based on these conclusions of experimental nature, the perspective of using solution E in the treatment of irresectable hepatic metastases is recommended.
